[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Kim HC, Nam SW, Cho YK, Jeong HJ, Kim SI, Kim SH, An CM, Kim IH, Kim SW, Lee SO, Lee ST: [A case of Non-Hodgkin's lymphoma in a patient with Crohn's disease]. Korean J Gastroenterol; 2006 Mar;47(3):233-7
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Non-Hodgkin's lymphoma in a patient with Crohn's disease].
  • Although adenocarcinoma is a well known complication of chronic inflammatory bowel disease, primary gastrointestinal lymphoma occurring in Crohn's disease is rare.
  • Microscopic examination of proximal descending colon revealed peripheral T cell lymphoma and other site of the descending colon was consistent with Crohn's disease.
  • The patient reached complete remission of malignant lymphoma after three cycles of combined chemotherapy.
  • He has been well for 10 months with sulfasalazine maintenance therapy but was admitted to the hospital due to spontaneous bowel perforation of ascending colon.
  • Right hemicolectomy was done, but the patient died of post-surgical recurrent mesenteric abscess and sepsis.
  • To the best of our knowledge, this is the first case of Non-Hodgkin's lymphoma complicating Crohn's disease in Korea which was confirmed by immunohistochemical studies.
  • [MeSH-major] Colonic Neoplasms / complications. Crohn Disease / complications. Lymphoma, T-Cell / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554679.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Yokoyama J, Fujimiya Y, Yamaguchi T, Shiga K, Saijo Y, Groveman DS, McBain JA, Suzuki Y, Ebina T: Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma. Am J Hematol; 2003 May;73(1):1-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma.
  • The most effective treatment for recurrent non-Hodgkin's lymphoma (NHL) appears to be a high-dose cytotoxic chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT).
  • However, it has been suggested that the presence of occult lymphoma cells in harvested marrow may be responsible for a significant fraction of treatment failures after HDC/ABMT.
  • The present study examined randomly accrued NHL patients, independent of their cytogenic grades, for the presence of cells bearing bcl-2/immunoglobulin heavy chain (IgH) gene rearrangements in lymph node (LN) biopsies and the bone marrow by polymerase chain reaction (PCR) and Southern blot hybridization combined with a classical culturing technique.
  • Among 41 NHL patients examined, bcl-2/IgH translocations were evident in LN biopsies and marrow from each of 10 follicular lymphoma patients, but not in any samples from 31 newly diagnosed diffuse lymphoma patients.
  • Marrow aspirates from several patients that were cultured using a one-week "triggering culture" followed by an extended period of conventional culture resulted in emergence of a monoclonal, IgH-rearranged, bcl-2-normal lymphoid cell population.
  • Such outgrowth was specifically seen in cultures of diffuse lymphoma marrow (7 of 28 evaluable patients).
  • Southern analysis for IgH rearrangement within LN biopsies and of cells cultured from marrow of individual diffuse lymphoma patients produced identical patterns, suggesting that the occult lymphoma cells present in harvested marrow were derived from the predominant lymphoma cell population represented within involved lymph nodes.
  • The culture of histologically occult lymphoma from diagnostic marrow and analysis of the derived cells by Southern blot hybridization can be used to detect potentially aggressive lymphoma cells within harvested marrow, despite their lack of bcl-2 gene rearrangement.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoradiography. Biopsy. Blotting, Southern. Bone Marrow / pathology. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. DNA, Neoplasm / analysis. Deoxyribonuclease BamHI. Deoxyribonuclease EcoRI. Deoxyribonuclease HindIII. Female. Gene Rearrangement. Genes, bcl-2 / genetics. Genetic Markers. Humans. Immunoglobulin Heavy Chains / genetics. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Male. Middle Aged. Polymerase Chain Reaction. Translocation, Genetic. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12701113.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / Immunoglobulin Heavy Chains; EC 3.1.21.- / Deoxyribonuclease BamHI; EC 3.1.21.- / Deoxyribonuclease EcoRI; EC 3.1.21.- / Deoxyribonuclease HindIII
  •  go-up   go-down


3. Sambade C, Berglund M, Lagercrantz S, Sällström J, Reis RM, Enblad G, Glimelius B, Sundström C: U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. Int J Cancer; 2006 Feb 1;118(3):555-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma.
  • Several patterns of association between Hodgkin and non-Hodgkin lymphomas are recognized, some of which support a common cellular origin or shared transformation events for both malignancies.
  • We describe the U-2940 cell line derived from a diffuse large B-cell lymphoma with some features consistent with mediastinal large B-cell lymphoma, clinically apparent 1 month after the initial course of chemotherapy for Hodgkin's disease, fulfilling the criteria for composite malignancies.
  • The cell line is negative for Epstein-Barr virus and no evidence of t(14;18) was found.
  • U-2940 cells display multiple chromosomal rearrangements similar to recurrent aberrations described in both Hodgkin and non-Hodgkin lymphomas, also partially shared by U-2932 derived from a B-cell lymphoma sequential to Hodgkin's disease.
  • The original large B-cell lymphoma and the U-2940 cell line bear microsatellite instability, an abnormality associated with particular subtypes of non-Hodgkin lymphomas and found in tissues involved by Hodgkin lymphoma.
  • Therefore, U-2940 cells bear several features known to occur in Hodgkin and in non-Hodgkin lymphomas, leading to the assumption that this cell line may constitute a useful tool to address elective pathways of lymphomagenesis and eventually the Hodgkin and non-Hodgkin lymphoma association.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Animals. Cell Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Colony-Forming Units Assay. DNA, Neoplasm / analysis. Epstein-Barr Virus Infections / etiology. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement. Herpesvirus 4, Human / pathogenicity. Humans. Immunoglobulin Heavy Chains / genetics. Mice. Mice, Nude. Spectral Karyotyping. Translocation, Genetic


Advertisement
4. Terui Y, Sakurai T, Mishima Y, Mishima Y, Sugimura N, Sasaoka C, Kojima K, Yokoyama M, Mizunuma N, Takahashi S, Ito Y, Hatake K: Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci; 2006 Jan;97(1):72-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
  • Recently, anti-CD20 (rituximab) and anti-Her2/neu (trastuzumab) antibodies have been developed and applied to the treatment of malignant lymphoma and breast cancer, respectively.
  • However, bulky lymphoma is known to be resistant to rituximab therapy, and this needs to be overcome.
  • Fresh lymphoma cells were collected from 30 patients with non-Hodgkin's lymphoma, the expression of CD20 and CD55 was examined by flow cytometry, and complement-dependent cytotoxicity (CDC) assays were carried out.
  • One complement-inhibitory protein, CD55, contributed to bulky lymphoma-related resistance to CDC with rituximab.
  • To overcome the resistance to rituximab by high expression of CD55 in bulky lymphoma masses, small interfering RNA (siRNA) was designed from the DNA sequence corresponding to nucleic acids 1-380 of the CD55 cDNA.
  • Introduction of this siRNA decreased CD55 expression in the breast cancer cell line SK-BR3 and in CD20-positive cells of patients with recurrent lymphoma; resistance to CDC was also inhibited.
  • This observation gives us a novel strategy to suppress bulky disease-related resistance to monoclonal antibody treatment.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD55 / metabolism. Complement System Proteins / drug effects. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Lymphoma / genetics. Lymphoma / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor. Humans. RNA Interference. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Rituximab

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2006; 97: 72-79).
  • (PMID = 16367924.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD55; 0 / RNA, Small Interfering; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


5. Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res; 2009 Feb 15;15(4):1496-503
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
  • The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma.
  • EXPERIMENTAL DESIGN: Pharmacokinetic assessment was done in 98 patients enrolled in a phase II study who received 14 or 18 mg/m2 of romidepsin as a 4-hour infusion on day 1 during their first treatment cycle.
  • ABCB1 2677G>T/A variant alleles tended toward a reduced clearance and lower volume of tissue distribution, but this was not supported by a statistical significance.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 [10716719.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4543-9 [18628469.001]
  • [Cites] Clin Pharmacol Ther. 2001 Aug;70(2):189-99 [11503014.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32 [12440223.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20 [14530907.001]
  • [Cites] Pharmacogenetics. 2004 Jun;14(6):381-5 [15247630.001]
  • [Cites] J Antibiot (Tokyo). 1994 Mar;47(3):301-10 [7513682.001]
  • [Cites] J Antibiot (Tokyo). 1994 Mar;47(3):315-23 [8175484.001]
  • [Cites] Mol Pharmacol. 1994 Oct;46(4):627-38 [7969041.001]
  • [Cites] Prostate. 2005 Feb 15;62(3):299-306 [15389787.001]
  • [Cites] Biol Pharm Bull. 2005 Jan;28(1):124-9 [15635176.001]
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Cancer Lett. 2005 Jun 28;224(2):311-9 [15914281.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7398-404 [16243813.001]
  • [Cites] J Clin Pharmacol. 2006 Mar;46(3):373-9 [16490813.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Clin Genitourin Cancer. 2006 Jun;5(1):57-60 [16859580.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3678-85 [16877737.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):2893-6 [16950614.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Eur J Clin Pharmacol. 2007 May;63(5):437-49 [17404720.001]
  • [Cites] Drug Metab Dispos. 2007 Aug;35(8):1400-7 [17496208.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404 [17913323.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):101-16 [17963024.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr 1;865(1-2):153-8 [18342585.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3312-8 [18519758.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92 [11381569.001]
  • (PMID = 19228751.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010621-04; United States / Intramural NIH HHS / / NIH0011335962; United States / Intramural NIH HHS / / Z01 BC010548-05; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antibiotics, Antineoplastic; 0 / Depsipeptides; 0 / P-Glycoprotein; 0 / P-Glycoproteins; CX3T89XQBK / romidepsin
  • [Other-IDs] NLM/ NIHMS96612; NLM/ PMC2707030
  •  go-up   go-down


6. Khubchandani S, Deeb G, Smiley SL, Battiwalla M, Paplham P, Brown K, Syta M, Hahn T, Cheney R, McCarthy PL Jr, Hong F: Fatal hyperacute graft-versus-host disease following denileukin diftitox treatment for recurrent t cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant; 2009 Jul;15(7):887-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal hyperacute graft-versus-host disease following denileukin diftitox treatment for recurrent t cell lymphoma after allogeneic stem cell transplantation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Diphtheria Toxin / administration & dosage. Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation. Interleukin-2 / administration & dosage. Lymphoma, T-Cell / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539223.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


7. Sarris AH, Phan A, Duvic M, Romaguera J, McLaughlin P, Mesina O, King K, Medeiros LJ, Rassidakis GZ, Samuels B, Cabanillas F: Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol; 2002 Jun 15;20(12):2876-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimetrexate in relapsed T-cell lymphoma with skin involvement.
  • Because trimetrexate (TMTX) enters cells by passive diffusion and is not polyglutamylated, its activity in relapsed T-cell lymphoma was investigated.
  • PATIENTS AND METHODS: Eligible patients had histologically confirmed relapsed T-cell lymphoma involving the skin, had received more than one previous regimen, were older than 16 years, had normal organ function, and had no CNS disease or serious infections, including human immunodeficiency virus.
  • Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sézary syndrome (14 with large-cell transformation), and two had peripheral T-cell lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Lymphoma, T-Cell, Cutaneous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Trimetrexate / pharmacology
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • Hazardous Substances Data Bank. TRIMETREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065565.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; UPN4ITI8T4 / Trimetrexate
  •  go-up   go-down


8. Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ: Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2000;6(5A):555-62
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
  • We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkin's lymphoma (NHL) using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT).
  • After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week intervals.
  • Phase 1 consisted of cyclophosphamide 7 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg per day and leukapheresis upon recovery from white blood cell nadir.
  • The hematopoietic cell product was enriched by Percoll gradient separation and purged with a B-cell or T-cell monoclonal antibody panel and complement.
  • The NHL histologies were diffuse large cell, follicular/diffuse mixed, small noncleaved cell, T-cell-rich B-cell, lymphoblastic, and peripheral T cell.
  • Nine were removed from the study after the first or second phase because of progressive disease (n = 5), poor hematopoietic cell mobilization (n = 1), excessive toxicity (n = 2), and chronic active hepatitis C (n = 1).
  • Treatment-related toxicities in the remaining 11 transplant recipients were cardiomyopathy, hemorrhagic cystitis, persistent cytopenias, acute renal failure, abnormal liver function test results, and infectious complications.
  • There were no treatment-related deaths.
  • We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with considerable acute and chronic toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Purging. Hematopoietic Stem Cell Mobilization / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Adult. Bone Marrow Diseases / chemically induced. Cardiomyopathies / chemically induced. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystitis / chemically induced. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug-Induced Liver Injury / etiology. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Hemorrhage / chemically induced. Humans. Infection. Leucovorin / administration & dosage. Life Tables. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Pilot Projects. Salvage Therapy. Survival Analysis. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11071261.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Tsunoda S, Kobayashi H, Inoue K, Izumi T, Akutsu M, Katano S, Ueda T, Shirai T, Masuda Y, Ohmine K, Nagashima T, Ueda M, Takagi S, Muroi K, Ozawa K, Kano Y: [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2007 Jun;34(6):885-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
  • We conducted a clinical study of MTX-HOPE (day 1, methotrexate 20 mg per os (po); day 2, hydrocortisone 100 mg intravenous (iv), vincristine 1 mg iv; day 3,4 sobuzoxane 400 mg po; etoposide 25 mg po, repeating every 2 or 3 weeks) in 14 relapsed or refractory patients with non-Hodgkin's lymphoma.
  • This newly developed MTX-HOPE therapy may be a promising treatment option for such patients as are intolerable for high-dose chemotherapies with PBSC rescue or wish for outpatient therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Male. Methotrexate / administration & dosage. Middle Aged. Neutropenia / chemically induced. Piperazines / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565251.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperazines; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; R1308VH37P / sobuzoxane; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Zamkoff KW, Matulis MD, Mehta AC, Beaty MW, Hutchison RE, Gentile TC: High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant; 2004 Mar;33(6):635-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma.
  • Primary systemic anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) has a poor prognosis.
  • This study sought to determine if high-dose therapy and ASCT results in long-term disease-free survival (DFS) in patients with recurrent, chemotherapy-sensitive ALK-negative ALCL.
  • All patients with non-Hodgkin's lymphoma (NHL) who underwent ASCT at Wake Forest University and Upstate Medical University from 1 January 1990 to 12 December 2002 were reviewed to determine if they had T-, B- or null-cell NHL that was CD30+/CD15-/ALK negative.
  • All 16 patients underwent ASCT at the time of first relapse and form the basis of this report.
  • International prognostic index scores in 12 patients at the time of relapse were: low 3, LI 6 and HI 3.
  • Of 15 patients, 13 relapsed after ASCT; one patient was lost to follow-up.
  • Of 15 patients, 10 have died; nine of recurrent disease.
  • In our experience, high-dose therapy and ASCT does not produce long-term DFS in patients with recurrent chemotherapy-sensitive ALK-negative ALCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases / analysis. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15004538.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


11. Bo LJ, Liang AB, Liu B, Chen YH, Wang F, Jin XP: [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma]. Ai Zheng; 2006 Dec;25(12):1553-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: There is no standard salvage regimen for patients with recurrent and refractory non-Hodgkin's lymphoma (NHL) so far.
  • This study was to investigate the efficacy of DICE (dexamethasone, isofosfamide, cisplatin, and etoposide) regimen on recurrent and refractory NHL, and observe the adverse events.
  • METHODS: Clinical records of 80 patients with recurrent and refractory NHL, who failed to get remission from CHOP regimen (cyclophosfamide, vincristine, and donaurubicin) and accepted DICE as a salvage regimen for 6 cycles, were reviewed.
  • Of the 80 patients, 25 were T-cell original, and the other 55 were B-cell original.
  • The complete remission (CR) rate was 27.5%.The total response rate was 48.0% for T-cell NHL and 60.0% for B-cell NHL.
  • The CR rate was 16.0% for T-cell NHL and 32.7% for B-cell NHL.
  • Myelosuppression, nausea, vomit, alopecia, and electrolytes disorder were major adverse events, and could be cured after treatment.
  • No chemotherapy-related death occurred.
  • CONCLUSION: DICE regimen is effective in treating recurrent and refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alopecia / chemically induced. Cisplatin / adverse effects. Cisplatin / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Remission Induction. Thrombocytopenia / chemically induced. Young Adult

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166385.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


12. Sturm A, Noppeney R, Reimer J, Ross B, Baumgart D, Sundermann T, Sadony V, Gerken G: [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. Dtsch Med Wochenschr; 2001 Mar 30;126(13):364-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection].
  • [Transliterated title] AIDS und Non-Hodgkin Lymphome--kardiale Erstmanifestation eines hochmalignen B-Zellymphoms nach 18 Jahren HIV-Infektion.
  • HISTORY AND FINDINGS: A 35-year-old man who, as a result of intravenous drug abuse, had become infected with HIV 18 years previously, was admitted with signs of right-heart failure.
  • DIAGNOSIS, TREATMENT AND COURSE: Endocarditis with atrial thrombi and recurrent pulmonary emboli was diagnosed and treated with antibiotics and anticoagulants.
  • Computed tomography of skull, thorax and abdomen did not demonstrate any significantly enlarged lymph nodes.
  • Exploratory thoracotomy revealed an infiltrating highly malignant centroblastic non-Hodgkin's lymphoma (NHL) of almost the entire free wall of the right atrium.
  • After two courses of chemotherapy (CHOP protocol) the size of the tumour had significantly decreased.
  • Even if the site is atypical and there is no lymphadenopathy, a lymphoma should be considered.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Echocardiography, Transesophageal. Heart Atria / pathology. Humans. Male. Prednisone / administration & dosage. Substance Abuse, Intravenous / complications. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332231.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol; 2003 Aug 15;21(16):3051-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
  • PURPOSE: This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Patients had indolent NHL and recurrent disease after at least one chemotherapy regimen.
  • Epratuzumab was administered intravenously at 120 to 1,000 mg/m2 over 30 to 60 minutes weekly for four treatments.
  • Median duration of objective response was 79.3 weeks (range, 11.1 to 143.3 weeks), with median time to progression for responders of 86.6 weeks by Kaplan-Meier estimate.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cell Adhesion Molecules. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Differentiation, B-Lymphocyte / immunology. Female. Half-Life. Humans. Lectins / immunology. Lymphocytes / drug effects. Male. Middle Aged. Sialic Acid Binding Ig-like Lectin 2

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Aug 15;21(16):3011-2 [12837808.001]
  • (PMID = 12837807.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 16814-02
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antineoplastic Agents; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab
  •  go-up   go-down


14. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol; 2005 Aug 1;23(22):5044-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each.
  • Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]).
  • Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores.
  • Patients with DLBCL had a median of three (range, one to eight) prior regimens (14% resistant to last treatment) and 71% had high intermediate-risk or high-risk International Prognostic Index scores.
  • RESULTS: Treatment was well tolerated, with toxicities principally infusion-related and predominantly grade 1 or 2.
  • Median time to progression for all indolent NHL patients was 17.8 months.
  • CONCLUSION: The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955901.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Lee WS, Chan TL, Koh MT, Ariffin WA, Lin HP: Acquired immunodeficiency syndrome presenting as childhood non-Hodgkin's lymphoma. Singapore Med J; 2001 Nov;42(11):530-3
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired immunodeficiency syndrome presenting as childhood non-Hodgkin's lymphoma.
  • Two children with non-Hodgkin's lymphoma (NHL) as the presenting illness of acquired immunodeficiency syndrome (AIDS) are described.
  • In the first case, an 18-month-old boy with stage IV, high-grade,T-cell NHL, the diagnosis of underlying AIDS was suspected only when he developed recurrent and profound opportunistic infection during chemotherapy.
  • She had progressive abdominal distension and swelling of her right eye one year later due to high grade B-cell NHL.
  • She was later found to be sero-positive for HIV during pre-chemotherapy screening.
  • [MeSH-major] Lymphoma, AIDS-Related / etiology. Lymphoma, B-Cell / etiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, T-Cell / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11876380.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


16. Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ: [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]. Ai Zheng; 2004 Aug;23(8):943-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
  • BACKGROUND & OBJECTIVES: The biological behavior of peripheral T-cell lymphoma (PTCL) are different from that of B-cell non-Hodgkin's lymphoma (NHL).
  • It shows low chemosensitivity, high incidence of relapse, poor prognosis, and has no standard chemotherapy regimen.
  • According to WHO classification criteria, 21 cases of PTCL concluded 7 peripheral T-cell lymphoma unspecified (PTCL-U), 7 NK/T-cell lymphoma (NK/TCL), 5 anaplastic large cell lymphoma (ALCL), 1 Mycosis fungoides/Sezary syndrome (MF/SS), and 1 subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
  • Among them there were 14 previously untreated patients, 7 pretreated and recurrent patients.
  • RESULTS: Of 21 patients, 20 were eligible to evaluate treatment efficacy.
  • The RRs of patients with NK/TCL, PTCL-U, and ALCL were 71.4% (5/7), 100.0% (6/6), and 80.0%(4/5); the CR rates were 57.1% (4/7), 50.0% (3/6), and 40.0% (2/5).
  • Seventy cycles of chemotherapy were administered to 21 patients.
  • Other toxicities were mild, no treatment-related mortality occurred.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15301720.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


17. Piekarz R, Frye R, Turner M, Wright J, Leonard J, Allen S, Bates S, for all collaborators: Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):3028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
  • : 3028 Background: Depsipeptide, FK228 (Fujisawa Pharmaceuticals), is the first of a new generation of histone deacetylase inhibitors to demonstrate consistent clinical activity in a specific tumor type.
  • As a result, we are currently conducting a multi-institutional phase II trial in patients with CTCL, PTCL, or other mature T cell lymphomas.
  • METHODS: This trial is accruing patients into 4 separate arms based on histology and prior therapy.
  • In Arm 1, comprised of patients with CTCL who had not previously received more than 2 cytotoxic chemotherapy regimens, objective responses were observed in 7 of 14 patients, including 3 patients with complete response and 4 patients with partial response, for a response rate of 50%.
  • Overall the drug is well tolerated, with observed toxicities including nausea, vomiting, fatigue, neutropenia, thrombocytopenia, and hypocalcemia.
  • Non-specific ST-T wave changes are noted by ECG, without changes in cardiac function.
  • CONCLUSIONS: These results suggest that histone deacetylase inhibitors such as depsipeptide are active in patients with T cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015193.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs; 2003;63(8):803-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
  • Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL).
  • While the optimal use of the drug in many clinical settings has yet to be clarified, two pivotal trials have established rituximab as a viable treatment option in patients with relapsed or refractory indolent NHL, and as a standard first-line treatment option when combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (the most common type of aggressive NHL).
  • The former was a noncomparative trial in relapsed indolent NHL (follicular and small lymphocytic subtypes) with clinical responses achieved in about half of patients treated with rituximab 375 mg/m(2) intravenously once weekly for 4 weeks, which was similar to some of the most encouraging results reported with traditional chemotherapeutic agents.
  • The latter was a randomised comparison of eight cycles of CHOP plus rituximab 375 mg/m(2) intravenously (one dose per cycle) versus CHOP alone in previously untreated elderly patients (60 to 80 years of age) with diffuse large B-cell lymphoma.
  • Treatment with rituximab is generally well tolerated, particularly in terms of adverse haematological effects and serious or opportunistic infections relative to standard chemotherapy.
  • CONCLUSIONS: Clinical trials with rituximab indicate that the drug has broad application to B-cell malignancies, although further clarification is needed to determine its optimal use in many of these clinical settings.
  • Importantly, rituximab in combination with CHOP chemotherapy has emerged as a new treatment standard for previously untreated diffuse large B-cell lymphoma, at least in elderly patients.
  • Compared with conventional chemotherapy, rituximab is associated with markedly reduced haematological events such as severe neutropenia, as well as associated infections.
  • Rituximab may be particularly suitable for elderly patients or those with poor performance status, and its tolerability profile facilitates its use in combination with cytotoxic drugs.
  • Although treatment with rituximab induces lymphopenia in most patients, typically lasting about 6 months, a full recovery of B lymphocytes in the peripheral blood is usually seen 9-12 months after therapy, as CD20 is not expressed on haematopoietic stem cells.
  • CD20 is, however, expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL) and to a lesser degree on B-cell chronic lymphocytic leukaemia (CLL) cells.
  • In addition, in vitro data indicate that rituximab sensitises tumour cells to the effects of conventional chemotherapeutic drugs.
  • PHARMACOKINETIC PROPERTIES: Serum rituximab concentrations increased in proportion to dose across a wide range of single- and multiple-dose intravenous regimens in patients with B-cell NHL.
  • When administered at a dose of 375 mg/m(2) once weekly for 4 weeks in a pivotal trial in patients with relapsed or refractory indolent B-cell NHL (follicular or small lymphocytic subtypes), peak serum concentrations essentially doubled from the first (239.1 mg/L) to the fourth (460.7 mg/L) infusion, while elimination half-life (t(1/2)) increased from 76.3 to 205.8 hours (3.2 to 8.6 days).
  • The pharmacokinetic properties of rituximab are also characterised by wide inter-individual variability, and serum drug concentrations that are correlated with clinical response.
  • Although pharmacokinetic data are limited in patients with aggressive forms of NHL, such as diffuse large B-cell lymphoma, rituximab appears to have a similar pharmacokinetic profile in these patients to that in patients with indolent B-cell NHL.
  • The pharmacokinetics of rituximab are also reported to be similar whether the drug is administered with or without cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
  • THERAPEUTIC USE: A number of studies have demonstrated efficacy of intravenous rituximab in patients with various lymphoid malignancies of B-cell origin, including indolent (e.g. follicular lymphoma) and aggressive (e.g. diffuse large B-cell lymphoma) forms of NHL, and CLL, but the drug has not yet been approved for use in CLL, and approved indications in NHL vary between countries.
  • In the US, for example, rituximab is available for the treatment of patients with low-grade or follicular, relapsed or refractory, CD20-positive B-cell NHL.
  • In Europe, the drug has similar approval for relapsed or refractory follicular NHL as in the US, but has also been approved for use in combination with CHOP chemotherapy for the most common aggressive form of NHL (CD20-positive, diffuse large B-cell lymphoma).
  • In Japan, rituximab has been approved for indolent B-cell NHL and mantle cell lymphoma (an aggressive form of B-cell NHL), primarily on the basis of results of a Japanese phase II trial.
  • Indolent NHL: Results of several studies evaluating rituximab 375 mg/m(2) once weekly for 4 weeks in patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic lymphomas) showed objective response (OR) rates ranging from approximately 40-60% in those receiving the drug for relapsed or refractory indolent B-cell NHL, and slightly higher (50-70%) for those receiving rituximab as first-line therapy.
  • In a pivotal trial in 166 patients with relapsed or refractory low-grade or follicular B-cell NHL, intent-to-treat (ITT) analysis showed an OR rate of 48%, and a projected median time to progression of 13 months.
  • CHOP, fludarabine-containing regimens) or other drugs (e.g. interferon-alpha2a) in previously untreated patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic subtypes).
  • Follow-up data from a study in 40 patients with low-grade or follicular B-cell NHL treated with rituximab plus CHOP as first-line therapy showed that responses were durable with a progression-free survival and median duration of response >5 years.Bcl-2 gene rearrangement (t14;18) occurs in malignant cells in up to 85% of patients with follicular lymphoma, and minimal residual disease in peripheral blood and bone marrow can be monitored using polymerase chain reaction (PCR).
  • Aggressive NHL: Studies with rituximab as monotherapy in aggressive B-cell NHL, a potentially curable disorder, have generally been restricted to patients with relapsed or recurrent disease, since CHOP has traditionally been the standard first-line treatment regimen.
  • However, promising results from phase II monotherapy studies prompted further clinical investigation of rituximab in conjunction with chemotherapy.
  • Thus, most studies with rituximab in patients with aggressive forms of B-cell NHL have involved combination therapy, including a pivotal randomised trial comparing eight cycles of standard CHOP therapy plus rituximab 375 mg/m(2) (one dose per cycle) versus CHOP alone in 399 previously untreated elderly patients (60-80 years of age) with diffuse large B-cell lymphoma.
  • Other, smaller trials with rituximab in combination with CHOP or other chemotherapeutic regimens, either as first-line therapy or for patients with relapsed or refractory aggressive B-cell NHL, have also shown promising results in terms of clinical response rates.CLL: In relatively small trials (n < 40) conducted primarily in patients with relapsed or refractory B-cell CLL, rituximab monotherapy (various regimens) achieved OR rates of 23-45%, with median duration of response ranging from approximately 3-10 months. (ABSTRACT TRUNCATED)
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Drug Administration Schedule. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96 [10561023.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):21-6 [12270058.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):477-81 [12688318.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):2-9 [28140087.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Ann Hematol. 2000 Jun;79(6):332-5 [10901614.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):2961-6 [11062708.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):30-35 [28140089.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):655-61 [10442187.001]
  • [Cites] Cell Immunol. 2000 Aug 25;204(1):55-63 [11006018.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):53-61 [11226001.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1038-43 [11807010.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):81-8 [10848785.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3115-20 [12384407.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2644-52 [10914705.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):995-1001 [9818074.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):836-45 [11895917.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):105-112 [28140083.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1658-64 [12886256.001]
  • [Cites] Jpn J Cancer Res. 1998 Jul;89(7):748-56 [9738982.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1096-7 [11822361.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):928-43 [12123339.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1392-8 [11222385.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1288-94 [11870171.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1991-2 [11565541.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):399-408 [10847457.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):374-5 [10811510.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1229-30 [12414357.001]
  • [Cites] Eur J Health Econ. 2002;3(3):166-72 [15609141.001]
  • [Cites] Eur J Haematol. 2002 Sep;69(3):129-34 [12406005.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):371-6 [12416894.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):70-74 [28140094.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22 [12040530.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):259-63 [1380203.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Clin Lymphoma. 2000 Sep;1(2):146-51; discussion 152-3 [11707827.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):47-54 [10444162.001]
  • [Cites] J Immunol Methods. 1997 Mar 28;202(2):163-71 [9107305.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1735-44 [12200688.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Blood Cells Mol Dis. 2000 Apr;26(2):133-43 [10753604.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Haematologica. 2002 Jul;87(7):719-29; discussion 729 [12091123.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2672; author reply 2673 [12360978.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):697-714; discussion 714, 717, 721 [9597680.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):56-69 [28140093.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Drugs. 1999 Jul;58(1):79-88; discussion 89-90 [10439931.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29 Suppl 1:S14-7 [11840156.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):109-14 [11249036.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):280-2 [11807154.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2771-7 [11675350.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7170-6 [11156427.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):41-47 [28140091.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3800-7 [8204898.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):75-80 [28140095.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):828-34 [12060117.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Clin Lymphoma. 2000 Dec;1(3):186-94; discussion 195-6 [11707828.001]
  • [Cites] Haematologica. 1998 Mar;83(3):209-16 [9573674.001]
  • [Cites] Ann Hematol. 2000 Sep;79(9):493-500 [11043420.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:123-6 [10707793.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]
  • [Cites] Leuk Res. 2000 May;24(5):411-5 [10785263.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3449-57 [8507880.001]
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):521-6 [10482937.001]
  • [Cites] J Clin Invest. 1981 Jan;67(1):134-40 [6969730.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] Blood. 2002 Feb 1;99(3):856-62 [11806987.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):36-40 [28140090.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 12662126.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 177
  •  go-up   go-down


19. Van Besien K: Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfus Apher Sci; 2005 Feb;32(1):45-53
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic stem cell transplantation in follicular lymphoma.
  • Follicular non-Hodgkin's lymphomas (NHL) usually present in advanced stage and although frequently are chemotherapy-sensitive remain incurable using conventional approaches.
  • Treatment options are evolving rapidly and now include targeted therapies such as monoclonal antibodies.
  • Recent studies, including the EBMTR-sponsored "CUP Trial" (conventional Chemotherapy, Unpurged autograft, Purged autograft), demonstrate that for patients under age 60 years with recurrent chemotherapy-sensitive disease, autologous stem cell transplantation (ASCT) provides a survival benefit over conventional therapy.
  • Allogeneic stem cell transplantation (alloSCT) has become a more effective option.
  • Although incorporation of TBI into the preparative regimen may increase treatment-related mortality (TRM), relapses appear to be reduced compared to a chemotherapy-alone regimen.
  • There are no clear means for choosing ASCT versus alloSCT, a decision influenced by amount of residual tumor, disease-responsiveness, degree of marrow involvement and extent of prior chemotherapy.
  • ASCT or alloSCT in first remission remains an investigational procedure.
  • Future considerations include incorporation of novel preparative regimens, in vitro purging techinques, anti-lymphoma vaccines, post-transplant immunotherapy and ex vivo-manipulated donor lymphocyte infusions.
  • [MeSH-major] Lymphoma, Follicular / therapy. Stem Cell Transplantation / methods. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Humans. Recurrence. Remission Induction. Transplantation Conditioning

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737873.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


20. Jillella AP, Day DS, Severson K, Kallab AM, Burgess R: Non-Hodgkin's lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha). Leuk Lymphoma; 2000 Jul;38(3-4):419-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha).
  • Both patients were treated with CHOP chemotherapy.
  • She relapsed two months later with recurrent edema that responded a second time to salvage chemotherapy.
  • As anasarca is an unusual presenting symptom of non-Hodgkin's lymphoma, we postulated that the malignant cells were secreting a cytokine that resulted in "vascular leakage" of fluid and development of diffuse edema.
  • [MeSH-major] Edema / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, T-Cell / complications. Neoplasm Proteins / physiology. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capillary Leak Syndrome / etiology. Cyclophosphamide / administration & dosage. Cytokines / blood. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Male. Prednisone / administration & dosage. Serum Albumin / deficiency. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Edema.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10830750.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Cytokines; 0 / Neoplasm Proteins; 0 / Serum Albumin; 0 / Tumor Necrosis Factor-alpha; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G: Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol; 2002 Jan;81(1):26-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study.
  • CAMPATH-1H (CP-1H) is a humanized monoclonal antibody directed against the CD52 antigen with promising therapeutic effects in patients with small cell lymphocytic non-Hodgkin's lymphomas (NHL) of B- and T-cell type.
  • We report about the response and toxicity of CP-1H in 18 patients with B-cell NHL who were treated in four clinical centers in Germany.
  • All patients had received chemotherapy before and had either relapsed or were refractory to conventional therapy.
  • Two patients received CP-1H in a dose-range finding trial once weekly and 16 patients as a fixed dose of 30 mg three times weekly.
  • Eleven patients suffered from bacterial or viral infections; some had recurrent infections.
  • Prophylactic treatment of the side effects is strongly recommended for patients treated either with CP-1H alone or in combination with chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11807632.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


22. Manoukian G, Hagemeister F: Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther; 2009 Nov;9(11):1445-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Information was obtained via the internet and a journal literature review.
  • RESULTS: In 1999, the FDA approved the use of denileukin diftitox for patients with persistent or relapsed CD25-positive cutaneous T-cell lymphoma (CTCL), but Ontak has been reported to be an effective therapy for other neoplastic and non-neoplastic conditions.
  • Oncological uses include therapy for CD25-negative T-cell lymphoma, recurrent and refractory chronic lymphocytic leukemia (CLL), non-Hodgkin's B-cell lymphoma (NHL), and human T-cell lymphotropic virus- 1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL).
  • Potential additional uses of Ontak include: therapy of graft-versus-host disease (GvHD) and autoimmune conditions, including psoriasis, rheumatoid arthritis (RA), systemic lupus, scleroderma and vasculitis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Humans. Recombinant Fusion Proteins / therapeutic use. United States. United States Food and Drug Administration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817678.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 37
  •  go-up   go-down


23. Natkunam Y, Stanton TS, Warnke RA, Horning SJ: Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab. Clin Lymphoma; 2001 Dec;2(3):185-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
  • A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma.
  • While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's and non-Hodgkin's lymphomas from which they must be distinguished for diagnosis and treatment.
  • We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Immunophenotyping. Liver / drug effects. Liver / pathology. Liver / radiography. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab. Spleen / drug effects. Spleen / pathology. Spleen / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779297.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


24. Kim R, Toge T: Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg Today; 2004;34(4):293-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
  • Recent advances in molecular biology have led to the development of selective molecular targeting agents for genes involved in cell proliferation, apoptosis, and angiogenesis in cancer cells.
  • The current success of molecular targeting therapy is shown by: imatinib mesylate (STI571, Gleevec), targeted to the Bcr/Abl fusion protein derived from a translocation between chromosomes 9 and 22 in chronic myelogenous leukemia; rituximab (Rituxan), a monoclonal antibody to CD20 used in non-Hodgkin's lymphoma; trastuzumab (Herceptin), a chimeric monoclonal antibody to HER-2 used in breast cancer; and gefinitib (ZD1839, Irresa), a tyrosine kinase inhibitor of the epidermal growth factor receptor used in non-small cell lung cancer.
  • The superior therapeutic efficacy of these molecular targeting agents over traditional chemotherapy has been shown by the survival benefit achieved for patients with advanced or recurrent cancers.
  • Although the precise molecular mechanisms by which these agents produce or enhance an antitumor effect, alone or in combination with anticancer drugs, are not known, the specific inhibition of target genes critically involved in tumor progression and metastasis by the agent is clear.
  • However, further studies to determine which patient groups and anticancer drugs are appropriate for combination therapy with these molecular targeting agents are needed.
  • Herein, we discuss the current status and potential for overcoming drug resistance in solid tumors and focus on the differential features of the tumor microenvironment in solid and hematologic malignancies.
  • [MeSH-major] Drug Resistance, Neoplasm. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Disease Progression. Fusion Proteins, bcr-abl. Humans. Imatinib Mesylate. Molecular Biology. Paracrine Communication / drug effects. Paracrine Communication / radiation effects. Piperazines / pharmacology. Piperazines / therapeutic use. Platelet-Derived Growth Factor / physiology. Protein-Tyrosine Kinases. Pyrimidines / pharmacology. Pyrimidines / therapeutic use. Quinazolines / pharmacology. Quinazolines / therapeutic use. Receptor, ErbB-2 / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15052442.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Pyrimidines; 0 / Quinazolines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.2 / Fusion Proteins, bcr-abl; P188ANX8CK / Trastuzumab; S65743JHBS / gefitinib
  • [Number-of-references] 81
  •  go-up   go-down


25. Usmani SZ, Sahay T, Eisenberg L: Angio-immunoblastic T-cell lymphoma in evolution: a case report. Adv Ther; 2007 Jul-Aug;24(4):814-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angio-immunoblastic T-cell lymphoma in evolution: a case report.
  • Angio-immunoblastic T-cell lymphoma (AITL), a rare disease that constitutes 1% to 2% of non-Hodgkin's lymphomas, presents in middle-aged and elderly individuals.
  • A computed tomography scan documented recurrent diffuse lymphadenopathy.
  • The patient developed sepsis during the second cycle and expired within 4 mo of diagnosis.
  • The prognosis and natural course of AITL are poor when the classic chemotherapy protocol is administered.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Flow Cytometry. Humans. Middle Aged. Sepsis / etiology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17901030.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


26. Selenko N, Majdic O, Jäger U, Sillaber C, Stöckl J, Knapp W: Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol; 2002 May;22(3):124-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?
  • Humanizing xenogenic monoclonal antibodies (MAbs) by genetic engineering has greatly improved their therapeutic utility and efficacy.
  • The chimeric CD20 MAb C2B8 (Rituximab) is a prominent representative of this new generation of therapeutic MAbs and has been proposed as a treatment of choice for recurrent follicular non-Hodgkin's lymphomas.
  • Treatment of CD20+ B cells with MAb C2B8 triggers several cell-damaging actions including complement-mediated lysis (CDL), antibody-dependent cellular cytotoxicity (ADCC), and MAb-induced induction of apoptosis.
  • We provide an overview of the most prominent mechanisms underlying the efficacy of antibody treatment.
  • We introduce our concept of cross-priming of cytotoxic T-cell responses promoted by apoptosis incucing antibodies.
  • Treatment of tumor cells with antibodies that are capable of inducing a proapoptotic signal via their cell surface target structure may not only contribute to their direct killing but also may induce cellular responses against the tumor, which may have a long-lasting protective effect.
  • We report, using the example of C2B8 anti-CD20 treatment of lymphoma cells, that MAb C2B8-induced apoptosis of lymphoma cells not only kills these cells but also promotes uptake and cross-presentation of lymphoma cell-derived peptides by antigen-presenting dendritic cells (DC), induces maturation of DC, and allows the generation of specific CTL.
  • [MeSH-minor] Animals. Antibodies, Heterophile / immunology. Antibodies, Heterophile / therapeutic use. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] J Exp Med. 1976 May 1;143(5):1283-8 [1083422.001]
  • [Cites] Science. 1995 Sep 15;269(5230):1585-8 [7545313.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Immunol Today. 2000 Aug;21(8):397-402 [10916143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2185-90 [10681453.001]
  • [Cites] J Immunol Methods. 1999 Feb 1;223(1):1-15 [10037230.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):747-52 [8760829.001]
  • [Cites] Cell Death Differ. 1999 Feb;6(2):183-9 [10200565.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Immunol. 1985 Aug;135(2):1530-5 [3874237.001]
  • [Cites] Nat Med. 2001 Mar;7(3):297-303 [11231627.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):423-34 [10662788.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):371-80 [9892619.001]
  • [Cites] Cell. 1985 Jul;41(3):697-706 [2860972.001]
  • [Cites] Immunol Today. 2000 Aug;21(8):403-10 [10916144.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):613-24 [10684853.001]
  • [Cites] Nature. 1998 Mar 5;392(6671):86-9 [9510252.001]
  • [Cites] Cell Death Differ. 1999 Mar;6(3):262-70 [10200577.001]
  • [Cites] Hematol Cell Ther. 1997 Nov;39 Suppl 1:S13-6 [9471057.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1145-57 [11677207.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1619-26 [11587221.001]
  • [Cites] Cancer Res. 1984 Mar;44(3):1002-7 [6318979.001]
  • [Cites] Curr Opin Immunol. 1997 Feb;9(1):10-6 [9039784.001]
  • [Cites] Blood. 1987 Feb;69(2):584-91 [3492224.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Immunology. 1998 Nov;95(3):427-36 [9824507.001]
  • [Cites] J Immunol. 1992 Apr 1;148(7):2207-16 [1545126.001]
  • [Cites] Nature. 2000 May 4;405(6782):85-90 [10811223.001]
  • [Cites] J Immunol. 1997 Dec 1;159(11):5391-9 [9548479.001]
  • [Cites] Annu Rev Immunol. 2001;19:47-64 [11244030.001]
  • [Cites] Curr Opin Immunol. 1999 Oct;11(5):541-7 [10508709.001]
  • [Cites] Eur J Immunol. 1997 Aug;27(8):1893-900 [9295024.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1184-90 [9694706.001]
  • [Cites] J Exp Med. 1998 Dec 7;188(11):2163-73 [9841929.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):879-85 [3871353.001]
  • [Cites] Immunol Today. 1994 Sep;15(9):450-4 [7524522.001]
  • [Cites] J Leukoc Biol. 1999 Aug;66(2):247-51 [10449162.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2842-9 [10072532.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • [Cites] Immunity. 1995 Dec;3(6):783-91 [8777723.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] J Exp Med. 1988 Feb 1;167(2):288-99 [3279151.001]
  • [Cites] Eur J Immunol. 1997 Jan;27(1):280-8 [9022030.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1644-52 [9473230.001]
  • [Cites] Curr Opin Hematol. 1998 Jul;5(4):237-43 [9747629.001]
  • [Cites] Tissue Antigens. 1995 Mar;45(3):177-87 [7761977.001]
  • [Cites] Blood. 1996 Jul 15;88(2):580-9 [8695806.001]
  • [Cites] J Exp Med. 1998 Oct 5;188(7):1359-68 [9763615.001]
  • (PMID = 12078853.001).
  • [ISSN] 0271-9142
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Heterophile; 0 / Antibodies, Neoplasm
  • [Number-of-references] 53
  •  go-up   go-down


27. Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS: Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):79-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
  • PURPOSE: For patients with recurrent or refractory large B-cell non-Hodgkin's lymphoma, high-dose chemotherapy and autologous stem cell transplant (ASCT) is the treatment of choice.
  • We evaluated the role of involved field radiation therapy (IFRT) post-ASCT for patients initially induced with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) or, more recently, rituximab-CHOP (R-CHOP).
  • MATERIALS AND METHODS: Between May 1992 and April 2005, 176 patients underwent ASCT for recurrent or refractory large B-cell non-Hodgkin's lymphoma; 164 patients were evaluable for endpoint analysis.
  • Follow-up from the time of transplant was a median/mean of 1.7/3 years (range, 0.03-13 years).
  • IFRT was associated with a 10% (p = 0.17) reduction in local failure, alone or with a distant site.
  • CONCLUSIONS: Recognizing that positive and negative patient selection bias exists for the use of IFRT post-ASCT, patients initially treated with CHOP or R-CHOP and who undergo ASCT for recurrent or refractory disease may benefit from subsequent IFRT presumably due to enhanced local control that can translate into a survival advantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Prednisone / administration & dosage. Remission Induction. Rituximab. Salvage Therapy / methods. Survival Analysis. Transplantation, Autologous. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647953.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


28. Rueda A, Casanova M, Quero C, Medina-Pérez A: Pralatrexate, a new hope for aggressive T-cell lymphomas? Clin Transl Oncol; 2009 Apr;11(4):215-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pralatrexate, a new hope for aggressive T-cell lymphomas?
  • Aggressive T-cell lymphomas represent a particularly poor-prognosis subgroup of lymphomas.
  • This is especially true for patients with recurrent or refractory disease who typically have a limited response to salvage therapy and an extremely poor overall survival.
  • There is thus a strong need to develop potentially active drugs for these malignancies.
  • Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1.
  • Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against T-cell lymphomas.The dose-limiting toxicity for pralatrexate is mucositis,which could be abrogated with folic acid and vitamin B12 supplementation.
  • Pralatrexate is now being evaluated in phase II clinical trials for the treatment of peripheral T-cell lymphoma, and in a phase I/II trial in combination with gemcitabine for the treatment of non-Hodgkin's lymphoma.
  • Because of the limited therapies available for aggressive T-cell lymphoma, pralatrexate could secure a niche for the treatment of this condition, provided on going clinical trials and future phase III trials confirm the efficacy of the drug.
  • [MeSH-major] Aminopterin / analogs & derivatives. Antineoplastic Agents / therapeutic use. Folic Acid Antagonists / therapeutic use. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):695-711 [12617871.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(4):313-8 [9744777.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(1):18-25 [6690069.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Feb;8(2):205-31 [18288923.001]
  • [Cites] J Clin Invest. 1979 Sep;64(3):788-97 [288743.001]
  • [Cites] J Med Chem. 1993 Jul 23;36(15):2228-31 [8340923.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):591-7 [16988580.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):835-43 [9789605.001]
  • [Cites] Lung Cancer. 1995 Apr;12 Suppl 1:S187-91 [7551928.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):153-81 [17333344.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):924-32 [16467107.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):410-26 [18297517.001]
  • [Cites] Br J Haematol. 2007 Nov;139(3):425-8 [17910632.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] IDrugs. 2008 Jul;11(7):508-21 [18600598.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):480-4 [18280345.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):767-74 [8398705.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3493-8 [10999734.001]
  • (PMID = 19380298.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Antineoplastic Agents; 0 / Folic Acid Antagonists; JYB41CTM2Q / Aminopterin
  • [Number-of-references] 31
  •  go-up   go-down


29. Kitabayashi K, Hasegawa T, Ueno K, Saito H, Kosaka T, Takashima S, Kurose N, Nojima T: Primary hepatic non-Hodgkin's lymphoma in a patient with chronic hepatitis C: report of a case. Surg Today; 2004;34(4):366-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic non-Hodgkin's lymphoma in a patient with chronic hepatitis C: report of a case.
  • We report a case of primary hepatic non-Hodgkin's lymphoma in a 77-year-old man with chronic hepatitis C.
  • Abdominal computed tomography showed that the tumor was marginally enhanced in the early phase, but no enhancement was seen in the late phase.
  • Histological examination confirmed a diagnosis of non-Hodgkin's diffuse large B-cell lymphoma that was positive for L-26 and CD79Alpha, but negative for CD3 and UCHL-1.
  • The surrounding liver tissue showed signs of chronic active hepatitis.
  • Multiple recurrent lesions were found in the liver, spleen, and iliac bones 4 months postoperatively.
  • However, complete remission was achieved after five courses of systemic chemotherapy using pirarubicin, cyclophosphamide, vincristine sulfate, and prednisolone.
  • We review the literature on primary non-Hodgkin's lymphoma arising in the liver infected by HCV.
  • [MeSH-major] Hepatitis C, Chronic / complications. Liver Neoplasms / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15052456.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Sarkodee-Adoo C, Pittarelli L, Jaffe E, Sorbara L, Raffeld M, Yao X, Haddad R, Heller T: Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy. Leuk Lymphoma; 2001 Sep-Oct;42(5):1125-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy.
  • An increased incidence of intermediate to high-grade Non Hodgkin's Lymphoma is found in individuals with AIDS.
  • Although immune function in AIDS patients can be improved through the use of antiretroviral therapy, the contribution of these drugs to lymphoma regression is not known.
  • Here we describe the complete regression and subsequent recurrence of high grade, Burkitt-like lymphoma during antiretroviral therapy in a patient with AIDS.
  • Antiretroviral therapy resulted in diminished viral load and modest improvement in CD4+ T cell counts.
  • Lymphoma regressed initially, but relapsed 3 months later.
  • Tissue taken from the initial and recurrent tumor demonstrated different clonal rearrangements.
  • The recurrent lymphoma did not respond to continued antiretroviral therapy.
  • In Conclusion, antiretroviral therapy may contribute to lymphoma regression in AIDS lymphoma.
  • Clinically recurrent disease may be clonally distinct.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma. Clone Cells / pathology. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary / pathology. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697632.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


31. Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1092-101
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
  • The aim of this study was to determine the feasibility, efficacy and toxicity of the combined therapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL).
  • Thirty six patients, 14 with mantle cell lymphoma (MCL), 10 with diffuse large B-cell lymphoma (DLBCL), 5 with follicular lymphoma (FL), 3 with small lymphocytic lymphoma (SLL), and 4 with T-cell lymphoma were enrolled to the study.
  • Seven of 19 patients with CR/PR are still in remission with a median follow-up of 3 months (range, 2-17 months).
  • There was a significant difference in OS between responders and nonresponders after CMC therapy (log rank test, P = 0.015).
  • When different disease status before CMC treatment was considered, a trend toward longer survival of recurrent patients was observed (log rank test, P = 0.08).
  • Grade 3-4 neutropenia developed in 14 (39%) patients, and 16 episodes (15%) of grade 3-4 infections were observed.
  • The results of our study show that the CMC regimen is effective salvage therapy with acceptable toxicity in heavily pretreated patients with NHL including MCL and DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cladribine / adverse effects. Cladribine / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Feasibility Studies. Female. Humans. Male. Middle Aged. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Salvage Therapy / adverse effects. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; CMC protocol 2
  •  go-up   go-down


32. McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL: A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant; 2004 Jan;33(1):19-24
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
  • The purpose of this study was to evaluate the efficacy and toxicity of the preparative regimen of thiotepa and etoposide in patients undergoing autologous transplantation for relapsed non-Hodgkin's lymphoma.
  • The study involved 65 consecutive patients who underwent autologous transplantation using the thiotepa/etoposide regimen for relapsed intermediate-grade NHL at the University of Wisconsin Hospital and Clinics (UWHC) between 1987 and 2001.
  • The median age at the time of transplant was 49 years.
  • A total of 50 patients (76%) had diffuse large-cell lymphoma.
  • With a median follow-up of 34 months (range, 3-163), 28 patients (43%) remain in CR and 33 (51%) have developed recurrent or progressive disease.
  • [MeSH-major] Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Thiotepa / administration & dosage. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Drug Resistance, Neoplasm. Female. Gastrointestinal Diseases / chemically induced. Humans. Male. Middle Aged. Remission Induction. Salvage Therapy / methods. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14704653.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


33. Fukuno K, Tsurumi H, Yamada T, Oyama M, Moriwaki H: Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation. Int J Hematol; 2001 Feb;73(2):262-5
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation.
  • Hemophagocytic syndrome (HPS) after hematopoietic stem cell transplantation can occasionally cause graft failure.
  • We describe a female patient with B-cell non-Hodgkin's lymphoma (NHL) with graft failure due to HPS 12 days after autologous peripheral blood stem cell transplantation (PBSCT).
  • Autologous PBSCT was carried out during unconfirmed/uncertain complete remission according to the Cotswolds classification after 6 cycles of biweekly (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy and 3 courses of salvage chemotherapy including etoposide.
  • The patient developed a high fever on day 2 post-PBSCT.
  • Her white blood cell count rose to 0.9 x 10(9)/L on day 10 post-PBSCT, but then began to decrease.
  • Although high-dose methylprednisolone therapy was continued, her white blood cell count further decreased to 0.3 x 10(9)/L, and the patient died of multiple organ failure on day 29 post-PBSCT.
  • A computed tomography scan did not identify recurrent NHL, and necropsy specimens from the bone marrow, liver, and kidney revealed no neoplastic infiltration.
  • HPS may have been induced by infection with methicillin-resistant Staphylococcus aureus rather than by lymphoma-associated HPS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Histiocytosis, Non-Langerhans-Cell / diagnosis. Histiocytosis, Non-Langerhans-Cell / etiology. Lymphoma, B-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1987 Jun;2(1):99-102 [3139115.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1219-22 [9894728.001]
  • [Cites] Bone Marrow Transplant. 1998 Mar;21(6):623-5 [9543068.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):131-7 [9722893.001]
  • [Cites] J Hematother. 1992 Winter;1(4):329-41 [1285382.001]
  • [Cites] Br J Haematol. 1993 Jan;83(1):21-7 [7679587.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):305-9 [1665315.001]
  • [Cites] Immunopharmacology. 1994 May-Jun;27(3):173-9 [8071057.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2918-22 [1954380.001]
  • [Cites] Bone Marrow Transplant. 1998 Feb;21(3):301-3 [9489656.001]
  • [Cites] Bone Marrow Transplant. 1990 Nov;6(5):349-52 [2291998.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4706-7 [8541568.001]
  • [Cites] Int J Hematol. 1997 Apr;65(3):215-26 [9114593.001]
  • [Cites] Br J Haematol. 1994 Jun;87(2):243-50 [7947264.001]
  • (PMID = 11372742.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


34. Carver JR, Nasta S, Chong EA, Stonecypher M, Wheeler JE, Ahmadi T, Schuster SJ: Myocarditis during lenalidomide therapy. Ann Pharmacother; 2010 Nov;44(11):1840-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocarditis during lenalidomide therapy.
  • OBJECTIVE: To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma.
  • CASE SUMMARY: An 85-year-old woman with recurrent follicular lymphoma was treated with lenalidomide 10 mg daily and low-dose dexamethasone 8 mg once weekly in a clinical trial.
  • Within 17 days of starting lenalidomide and dexamethasone, she developed symptoms and signs of congestive heart failure.
  • DISCUSSION: Lenalidomide is an immunomodulatory agent derived from thalidomide and is approved for the treatment of multiple myeloma and myelodysplastic syndromes.
  • The efficacy of lenalidomide has been reported in B-cell malignancies.
  • We propose an immunological mechanism for myocarditis based on the predominantly T-cell infiltration of the myocardium.
  • CONCLUSIONS: Our findings suggest that lenalidomide may be a cause of drug-induced myocarditis.
  • When patients treated with lenalidomide present with signs and symptoms of heart failure in the absence of other obvious causes, lenalidomide hypersensitivity should be considered in the differential diagnosis and a myocardial biopsy should be considered when other common causes of heart failure have been excluded.
  • A reasonable management approach is drug discontinuation and early institution of corticosteroid therapy.
  • An objective causality assessment, using the Naranjo probability scale, revealed that the adverse drug event was probable.
  • [MeSH-minor] Aged, 80 and over. Autopsy. Dexamethasone / therapeutic use. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Multiple Organ Failure / etiology. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876827.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


35. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J: Lessons learned from independent central review. Eur J Cancer; 2009 Jan;45(2):268-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Independent central review (ICR) is advocated by regulatory authorities as a means of independent verification of clinical trial end-points dependent on medical imaging, when the data from the trials may be submitted for licensing applications [Food and Drug Administration.
  • United States food and drug administration guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics.
  • London, UK: European Medicines Agency; 2006; United States Food and Drug Administration Center for Drug Evaluation and Research.
  • Rockville, MD: US Department of Health and Human Services; 2002; United States Food and Drug Administration Center for Drug Evaluation and Research.
  • Rockville, MD: US Department of Health and Human Services; 2005; United States Food and Drug Administration Center for Drug Evaluation and Research.
  • Rockville, MD: US Department of Health and Human Services; 2007; United States Food and Drug Administration Center for Drug Evaluation and Research.
  • Rockville, MD: US Department of Health and Human Services; 2007; United States Food and Drug Administration Center for Biologics Evaluation and Research.
  • Rockville, MD: US Department of Health and Human Services; 1997; United States Food and Drug Administration.
  • FDA Center for Biologics Evaluation and Research; 1998; United States Food and Drug Administration.
  • FDA Briefing Document Oncology Drugs Advisory Committee meeting NDA 21801 (satraplatin).
  • Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
  • JCO 2007(August):3407-14; Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
  • Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
  • Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study-FFCD 9803.
  • [MeSH-major] Clinical Trials as Topic. Neoplasms / therapy. Peer Review, Research / standards
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Humans. Treatment Outcome. Validation Studies as Topic

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101138.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement